For people with recurrent or metastatic nasopharyngeal cancer (NPC), a cancer that starts in the upper throat, finding effective treatments is critical. A new analysis pooled data from 883 patients across nine studies to understand what happens when they receive a type of drug called a PD-1/PD-L1 inhibitor. These drugs, known as immune checkpoint inhibitors, work by helping the body's own immune system fight the cancer.
The analysis found that, on average, patients lived without their cancer getting worse for about 4.2 months. They lived for about 16.3 months overall. Looking at one-year milestones, about 43% of patients were alive without their cancer progressing, and 80% were still alive. The treatment shrank the cancer in about 45% of patients and controlled it (either shrinking or stopping its growth) in about 65%.
However, side effects were very common. About 90% of patients experienced some side effect, and serious side effects (grade 3 or higher) happened in about 34% of patients. The analysis concludes that while this summarizes the current evidence on how well these drugs work and their safety, more high-quality randomized trials are needed to confirm their role.